Use of Karbinal ER may result in decreased mental alertness
with impaired mental or physical abilities [see WARNINGS AND PRECAUTIONS].
The most frequent adverse reactions include:Â sedation,
sleepiness, dizziness, disturbed coordination,Â epigastric distress, and
thickening of bronchial
secretions. In clinical use, younger children and older
adults may be particularly sensitive to adverse reactions [see Pediatric Use and Geriatric Use].
The following adverse reactions, listed by body system, have
been identified in case reports and during the use of carbinoxamine in
observational studies. Because these reactions are reported voluntarily from a
population of uncertain size, it is not always possible to reliably estimate
their frequency or establish a causal relationship to drug exposure.
Body as a Whole: Urticaria, drug rash, anaphylactic
shock, photosensitivity, excessive perspiration,Â chills, dryness of mouth, nose
Cardiovascular: Hypotension, headache, palpitations,
Central Nervous System: Fatigue, confusion,
restlessness, excitation, nervousness, tremor,Â irritability, insomnia,
euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute
labyrinthitis,Â hysteria, neuritis, convulsions.
Gastrointestinal: Anorexia, nausea, vomiting,
Hematologic: Hemolytic anemia, thrombocytopenia,
Laboratory: Increase in uric acid levels.
Respiratory: Tightness of chest and wheezing, nasal
Urogenital: Urinary frequency, difficult urination,
urinary retention, early menses.
Use of Karbinal ER is contraindicated in patients who are
taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the
anticholinergic (drying) effects of antihistamines.
Avoid use of Karbinal ER with alcohol and other CNS
depressants (hypnotics, sedatives, tranquilizers,Â etc.) due to additive